Insulin-like growth factor 1 receptor (IGF-1R) inhibitor: another arrow in the quiver - Will it hit the moving target? Expert Opin Investig Drugs 2011 Nov;20(11):1471-7
Date
09/23/2011Pubmed ID
21936711DOI
10.1517/13543784.2011.619978Scopus ID
2-s2.0-80053959825 (requires institutional sign-in at Scopus site) 2 CitationsAbstract
Insulin-like growth factor 1 receptor (IGF-1R) inhibitors have anti-tumor activity in various cancers. The development of IGF-1R inhibitors is a multi-dimensional and complex issue, involving many different drugs, and affecting several different points along the pathway. Matching patients with these agents based on molecular profiling/signatures will be essential for the proper development of this type of targeted agent.
Author List
Subbiah V, Angelo LS, Kurzrock RAuthor
Razelle Kurzrock MD Center Associate Director, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Antibodies, MonoclonalAntineoplastic Agents
Humans
Insulin-Like Growth Factor I
Signal Transduction